Research progress on the relationship between intestinal microecology and immunity in patients with chronic kidney disease

doi:10.3877/cma.j.issn.2095-3216.2024.02.008

Abstract

Abstract:

Intestinal microorganisms constitute the intestinal microecosystem of human body, and participate in physiopathological functions such as nutrition, metabolism, and immunity. Research findings have indicated that intestinal microecology is closely related to chronic kidney disease. By participating in the innate and adaptive immune responses of patients, intestinal microecology profoundly influences the progression of chronic kidney disease and its associated complications. Moreover, the intestinal mucosal immunity constructed by intestinal flora directly affects the production and secretion of IgA, thus affecting the occurrence and progression of IgA nephropathy. This article reviewed the research progress on the relationship between intestinal microecology and immunity in patients with chronic kidney disease, in order to provide new clues and ideas for the diagnosis and treatment of CKD.

Key words: Chronic kidney disease, Intestinal microecology, Immunity

Yansheng Wu, Xianwen Zhang, Lin Wang. Research progress on the relationship between intestinal microecology and immunity in patients with chronic kidney disease[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(02): 101-105.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2024.02.008

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2024/V13/I02/101

Figures/Tables 1

References 36

[1]	Mayorgas A, Dotti I, Salas A. Microbial metabolites, postbiotics, and intestinal epithelial function [J]. Mol Nutr Food Res, 2021, 65(5): e2000188.
[2]	Hobby GP, Karaduta O, Dusio GF, et al. Chronic kidney disease and the gut microbiome [J]. Am J Physiol Renal Physiol, 2019, 316(6): F1211-F1217.
[3]	Yang T, Richards EM, Pepine CJ, et al. The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease [J]. Nat Rev Nephrol, 2018, 14(7): 442-456.
[4]	Glorieux G, Gryp T, Perna A. Gut-derived metabolites and their role in immune dysfunction in chronic kidney disease [J]. Toxins (Basel), 2020, 12(4): 245.
[5]	Ma H, Qiu Y, Yang H. Intestinal intraepithelial lymphocytes: maintainers of intestinal immune tolerance and regulators of intestinal immunity [J]. J Leukoc Biol, 2021, 109(2): 339-347.
[6]	Andersen K, Kesper MS, Marschner JA, et al. Intestinal dysbiosis, barrier dysfunction, and bacterial translocation account for CKD-related systemic inflammation [J]. J Am Soc Nephrol, 2017, 28(1): 76-83.
[7]	Guiteras R, Flaquer M, Cruzado JM. Macrophage in chronic kidney disease [J]. Clin Kidney J, 2016, 9(6): 765-771.
[8]	Wen, Li, Ley, et al. Innate immunity and intestinal microbiota in the development of type 1 diabetes [J]. Nature, 2008, 455(7216): 1109-1113.
[9]	Zhou WQ, Sonnenberg GF. Activation and suppression of group 3 innate lymphoid cells in the gut [J]. Trends Immunol, 2020, 41(8): 721-733.
[10]	Li S, Bostick JW, Zhou L. Regulation of innate lymphoid cells by aryl hydrocarbon receptor [J]. Front Immunol, 2018, 8: 1909.
[11]	Wing MR, Patel SS, Ramezani A, et al. Gut microbiome in chronic kidney disease [J]. Exp Physiol, 2016, 101(4): 471-477.
[12]	Wingender G, Stepniak D, Krebs P, et al. Intestinal microbes affect phenotypes and functions of invariant natural killer T cells in mice [J]. Gastroenterology, 2012, 143(2): 418-428.
[13]	梁开阳，孙志洪，谭支良，等. 丁酸介导下肠道菌群与宿主免疫互作机制的研究进展[J]. 畜牧兽医学报，2021, 52(10): 2710-2720.
[14]	喻静，彭红英. 肠道菌群介导的免疫反应与高血压和慢性肾脏病的关系研究进展[J]. 解放军医学杂志，2021, 46(9): 865-870.
[15]	Song J, Noel S, Pluznick JL, et al. Gut microbiota-kidney cross-talk in acute kidney injury [J]. Semin Nephrol, 2019, 39(1): 107-116.
[16]	Schnell A, Littman DR, Kuchroo VK. TH17 cell heterogeneity and its role in tissue inflammation [J]. Nat Immunol, 2023, 24(1): 19-29.
[17]	Ma DH, Yang XD, Hua QJ, et al. Changes and significance of Treg and Th17 in adult patients with primary membranous nephropathy [J]. Clin Nephrol, 2021, 96(3): 155-164.
[18]	Dhana E, Ludwig-Portugall I, Kurts C. Role of immune cells in crystal-induced kidney fibrosis [J]. Matrix Biol, 2018, 68-69: 280-292.
[19]	Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease [J]. Cell Res, 2020, 30(6): 492-506.
[20]	Wang S, Charbonnier LM, Magali NR, et al. MyD88 adaptor-dependent microbial sensing by regulatory T cells promotes mucosal tolerance and enforces commensalism [J]. Immunity, 2015, 43(2): 289-303.
[21]	Chi M, Ma K, Wang J, et al. The immunomodulatory effect of the gut microbiota in kidney disease [J]. J Immunol Res, 2021, 2021: 5516035.
[22]	Lu Y, Yuan X, Wang M, et al. Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies [J]. J Hematol Oncol, 2022, 15(1): 47.
[23]	Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients [J]. Science, 2018, 359(6371): 97-103.
[24]	Vétizou M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota [J]. Science, 2015, 350(6264): 1079-1084.
[25]	Chaput N, Lepage P, Coutzac C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab [J]. Ann Oncol, 2017, 28(6): 1368-1379.
[26]	Barratt J, Rovin BH, Cattran D, et al. Why target the gut to treat IgA nephropathy? [J]. Kidney Int Rep, 2020, 5(10): 1620-1624.
[27]	Mielenz M, Kuhla B, Hammon HM. Abundance of adiponectin system and G-protein-coupled receptor GPR109A mRNA in adipose tissue and liver of F2 offspring cows of Charolais × German Holstein crosses that differ in body fat accumulation [J]. J Dairy Sci, 2013, 96(1): 278-289.
[28]	Zhong Z, Tan J, Tan L, et al. Modifications of gut microbiota are associated with the severity of IgA nephropathy in the Chinese population [J]. Int Immunopharmacol, 2020, 89(Pt B): 107085.
[29]	He JW, Zhou XJ, Li YF, et al. Associations of genetic variants contributing to gut microbiota composition in immunoglobin a nephropathy [J]. mSystems, 2021, 6(1): e00819-e00820.
[30]	Tezuka H, Ohteki T. Regulation of IgA production by intestinal dendritic cells and related cells [J]. Front Immunol, 2019, 10: 1891.
[31]	Pabst O, Slack E. IgA and the intestinal microbiota: the importance of being specific [J]. Mucosal Immunol, 2020, 13(1): 12-21.
[32]	Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation [J]. Cell, 2014, 157(1): 121-141.
[33]	Stanley JC, Deng H. Progress in pathogenesis of immunoglobin a nephropathy [J]. Cureus, 2020, 12(6): e8789.
[34]	Sallustio F, Curci C, Chaoul N, et al. High levels of gut-homing immunoglobulin A＋ B lymphocytes support the pathogenic role of intestinal mucosal hyperresponsiveness in immunoglobulin A nephropathy patients [J]. Nephrol Dial Transplant, 2021, 36(3): 452-464.
[35]	Sanchez-Russo L, Rajasekaran A, Bin S, et al. The gut and kidney crosstalk in immunoglobulin a nephropathy [J]. Kidney360, 2022, 3(9): 1630-1639.
[36]	邹荥，杜红莲. 新加肾元汤联合一体化治疗对慢性肾功能衰竭失代偿期患者的临床疗效[J]. 系统医学，2022, 7(18): 50-53.

Please choose a citation manager

Content to export